Metraipolis › archive › dc_87d07fea2732
Real-world safety comparison between cenobamate and lacosamide: a pharmacovigilance study based on the FDA Adverse Event Reporting System — Europe PMC PMID:40963942
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/40963942
- DOI
- 10.3389/fneur.2025.1625612
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-10T04:22:31.848Z
- SHA-256 of the archived text
4108af97ae1eb8fb28a1a5b3d83d1a14198efca68c86145b70338949dcf1dcbd- Stable URL of this page
https://metraipolis.com/documento/dc_87d07fea2732
How to cite
Real-world safety comparison between cenobamate and lacosamide: a pharmacovigilance study based on the FDA Adverse Event Reporting System — Europe PMC PMID:40963942 — Europe PMC (en), https://europepmc.org/article/MED/40963942 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_87d07fea2732 (Metraipolis archive dc_87d07fea2732, sha256 4108af97ae1eb8fb28a1a5b3d83d1a14198efca68c86145b70338949dcf1dcbd)
BibTeX
@misc{dc87d07fea2732,
title = {Real-world safety comparison between cenobamate and lacosamide: a pharmacovigilance study based on the FDA Adverse Event Reporting System — Europe PMC PMID:40963942},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/40963942},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_87d07fea2732; sha256 4108af97ae1eb8fb28a1a5b3d83d1a14198efca68c86145b70338949dcf1dcbd},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40963942. Agents can read the archived copy with the MCP tool read_document.